secwatch.observer — SEC 8-K summary
======================================

Issuer:     Keros Therapeutics, Inc. (KROS)
CIK:        0001664710
Form:       8-K
Filed at:   2024-06-17T23:59:59+00:00
Accession:  0001664710-24-000059
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Keros Therapeutics files prospectus supplement for up to $350M at-the-market stock offering
--------------------------------------------------------------------------------

- Filed prospectus supplement on June 17, 2024 to sell up to $350 million of common stock via ATM program.
- Leerink Partners acts as sales agent, earning a commission of up to 3.0% of gross proceeds.
- Sales may be made directly on the Nasdaq Global Market; company not obligated to sell any shares.
- Original sales agreement dated May 3, 2021; shelf registration statement effective May 3, 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1664710/000166471024000059/0001664710-24-000059-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1664710/000166471024000059/kros-20240617.htm
  HTML page:      https://secwatch.observer/filing/0001664710-24-000059

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer